Arbutus Biopharma Corp
ABUS
查看详细走势图
3.840USD
+0.170+4.63%
收盘 02/06, 16:00（美东）报价延迟15分钟
737.10M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+4.63%
5天
-7.02%
1月
-21.31%
6月
+12.94%
今年开始到现在
-20.17%
1年
+11.95%
查看详细走势图
TradingKey Arbutus Biopharma Corp股票评分
单位: USD 更新时间: 2026-02-06操作建议
Arbutus Biopharma Corp当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名88/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价5.67。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Arbutus Biopharma Corp评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Arbutus Biopharma Corp亮点
亮点风险
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
业绩增长期
公司处于发展阶段，最新年度总收入6.17M美元
估值低估
公司最新PE估值-17.40，处于3年历史低位
机构加仓
最新机构持股120.46M股，环比增加0.01%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值14.77K
分析师目标
根据
3
位分析师
买入
评级
5.667
目标均价
+46.05%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Arbutus Biopharma Corp新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Arbutus Biopharma Corp简介
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on infectious disease. The Company is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.
公司代码ABUS
公司Arbutus Biopharma Corp
CEOAndroski (Lindsay)
网址https://www.arbutusbio.com/
相关品种
